Replies to post #30203 on BioCurex, Inc.(fka BOCX)

[The Dutchess]

BOCX .0012's up!


Negative,Maybe shouldn't have sold though
GLTA, This should run to at least .0016 now IMO.

[Gold Seeker]

Seann, OK, my post are mostly negative because that is what is actually happening with the company.

If you read the lastest filings, this is what you would learn.

All of the independent directors have resigned.

They are no longer working on any human aspect of a cancer test.

They are attempting to sell Dog RECAF but sales in the last quarter have dropped by 40%. His next stated goal is to attempt to market a Cat RECAF test.

He is default to Richard Smithline for a $535,000 note due in December of this year. He has not been paying Smithline any percentage of money raised as it is requird in the contract with Smithline.

I guarantee you that Smithline will go after any assets remaining.

Moro has his own personal company, Pacific BioSciences, that does all the work for BioCurex at a 15% profit. Moro is in turn double dipping and getting large refunds from Revenue Canada and he is personally keeping the money. That money should go back to Bio
Curex and not in his pocket.

He is within 100,000 million of the max authorized shares and when they are issued, there is no more ability to pay employees, services or raise additional cash from Asher.

There is absolutely NOTHING positive happening with this company.

[Gold Seeker]

Seann, Asher is not the only negative thing about this company

1. Dog RECAF is NOT selling well at all. Meager revenues and it dropped 40% in the last quarter to $6,000.

2. Work on human products has ceased. Moro has mentioned the next product as Cat RECAF which wont sell either.

3. Moro has laid off almost all of his employees at his private firm which does all the contract work for BioCurex a ripoff rates.

4. Moro is personally pocketing all of the research rebate money from the Canadian Revenue Authority. That adds up to over $1.5 million in the past two years.

5. BioCurex is broke. Cash is limited to what he can borrow from Asher and pay back in shares discounted 58% to current share price.

6. BioCurex owes about $550,000 to hedge funds run by Richard Smithline due in December. There is no way he can pay it.

7. Moro has scammed the past two shareholder meeting votes by exercising options, voting and then unexercising the options. In the last vote, he bought 80 million shares and after voting, sold them back to Biocurex.

8. BioCurex China is a scam with no employees.